Podcast | AANEM 2025: Conference Review and Analysis for New Data on Emerging BAFF/APRIL Inhibitors for the Management of Patients with Generalized Myasthenia Gravis

Course Title for Certificate

Name*

First NameLast Name

Email*

example@example.com

What best describes your title?*

If PharmD, DOB

Date

If PharmD, NABP ID#:

1. What is the scientific rationale of the reported efficacy for telitacicept when controlled trials with the two other similar B cell trophic factors, atacicept and belimumab, and one anti-B cell agent, rituximab, were ineffective in generalized myasthenia gravis (gMG)?*

a. Telitacicept has dual efficacy by inhibiting both BAFF and APRILb. Telitacicept binds to TACI with enhanced stabilityc. Telitacicept can suppress CD19-B lymphocyte proliferationd. Telitacicept affects the maturation and survival of long-lived plasma cellse. All of the above

2. That rationale for performing a trial with telitacicept in gMG is that:*

a. BAFF is increased in the serum of MG patientsb. TACI suppresses AChR antibodies in experimental MGc. Both BAFF and TACI impair the stability of the NMJ by binding to the end plated. TACI enhances the production of AChR antibodiese. None of the above

3. The primary endpoint in the recent phase 3, double blinded, placebo controlled telitacicept myasthenia gravis trial was:*

a. The change from baseline in the QMG Score compared to placebo at week 24b. The change from baseline in the MG-ADL Score compared to placebo at week 48c. The change from baseline in the MG Composite Score compared to placebo at week 24d. The change from baseline in the MG-ADL Score compared to placebo at week 24e. The change from baseline in the QMG Score compared to placebo at week 48

4. A significant observation in the recent phase 3, double blinded, placebo controlled telitacicept myasthenia gravis trial was:*

a. A placebo adjusted MG-ADL score of -6.4 points at week 24b. Onset of effect within 1 to 2 weeks similar to recent FcRn blocker trialsc. Onset of effect within 1 week, similar to recent complement 5 inhibitor trialsd. Similar reductions in serum IgG, IgM, IgA and total B-cell counts approximating 70% were seene. The percentage of patients receiving telitacicept who achieved a ≥ 3 point change in MG-ADL score was 98%

How many patients do you currently see each year with myasthenia gravis?

How many years have you been in practice?

Learning Objectives

	Poor	Fair	Good	Very Good	Excellent
Analyze relevant new data on BAFF/APRIL inhibitors discussed at AANEM 2025 for the most up-to-date information on emerging treatment approaches to gMG
Evaluate the potential role of emerging BAFF/APRIL inhibitor therapies to manage and improve outcomes in patients with gMG

Please provide us with feedback regarding your experience at the activity:

	Poor	Fair	Good	Very Good	Excellent
Overall
Content
Usefulness

Do you feel this activity was fair, balanced, and free of commercial bias?

YesNo

If no, please explain:

This educational activity will result in a change in my role as a healthcare team member.

YesNoN/A

Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:

I gained new strategies/skills/information that my team can apply to practiceI plan to implement new strategies/skills/information in my practiceI will be more competent in my team’s management of patient careI will improve my communication with the healthcare team

What factors beyond clinical care that effect the health of your patients does your team experience?

Attestation:

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM .

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour, including 1.0 Pharmacotherapeutic Contact Hour (Provider #P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEUs) of Continuing Pharmacy Education Credit (JA4008190-0000-25-034-H01-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Date

Credits